Meanwhile,
Methods implementation infant newborn immunization:
As a reminder, three drugs are marketed and reimbursed by health insurance:
- A vaccine: Abrysvo;
- Two monoclonal antibodies: Beyfortus (Nirsévimab) and Synagis (Palivizumab).
1. However, Calendar and populations eligible for immunization against VRS infections for the 2025-2026 season – Methods implementation infant newborn immunization
1.1 Start dates of the vaccination. Nevertheless, immunization campaign – Methods implementation infant newborn immunization
|
Start of the campaign |
Territories concerned |
|
1is September 2025 |
Metropolitan France, Réunion, Martinique, Guadeloupe, Saint Martin and Saint Barthélémy |
|
1is August 2025 |
Guyane |
|
1is October 2025 |
Mayotte |
1.2 Children exposed to their 1st VRS traffic season
Maternal vaccination against the VRS (Abrysvo) and the immunization of the infant by preventive treatment (Beyfortus or Synagis) are the two possible strategies for prevention of VRS infections of newborns and infants exposed to their first VRS circulation season. However, It is up to parents. Furthermore, informed by health professionals, to decide on the strategy that suits them best, in order to methods implementation infant newborn immunization protect them.
Health professionals are invited to check the mother’s vaccination status before any immunization of newborns or infants by monoclonal antibody (Synagis or Beyfortus) in order to avoid double immunizations.
– The Abrysvo vaccine
This vaccine is aimed at pregnant women between the 32nd and 36th week of amenorrhea from the start of the campaign (cf. Additionally, 1.1). The immunization efficiency of this vaccine is observed from 2 weeks after injection and up to 6 months after childbirth.
– Monoclonal antibodies: Beyfortus (Nirsévimab). Synagis (Palivizumab)
Immunization by monoclonal antibodies (for the respective indications, refer to RCP) is aimed at all children knowing their first exhibition season at the VRS:
- For children to be born from the start date of the campaign (cf. 1.1). provided that the mother was not vaccinated by Abrysvo in order to avoid double immunizations;
- For children born between February and August 2025, Beyfortus or Synagis, as methods implementation infant newborn immunization a catch -up.
1.3 Children exposed to their 2nd VRS traffic season. who remain vulnerable
For children up to the age of 24 months that remain vulnerable (cf. Avis has) to a severe infection due to the VRS. knowing their second season of VRS traffic, only Beyfortus and Synagis are indicated (cf. RCP).
Beyfortus is not subject to management in this indication when the DGS-Urgent is published. However. administrative procedures are underway with the laboratory for its management for its indication re-immunization against the VRS of children who remain vulnerable to severe infection during their second VRS traffic season. The care will be effective to the publication of the decree dedicated to the Official Journal.
2. Provision and management available to medication
Only Beyfortus and Abrysvo are available in town. Synagis, Beyfortus and Abrysvo are available in health establishments and registered on the list of specialties approved for communities.
These specialties methods implementation infant newborn immunization will be made available in the city and in health establishments via the classic supply circuits and according to the calendars presented above.
The date of support for these treatments coincides with the start-up calendars of the 2025-2026 immunization campaign.
Source :
Further reading: Demoustication and prevention operations carried out after the report of a case of chikungunya in the Gard – Toxic seminal insects – Warning of public health | Lyme disease is well installed in the Laurentians – CIME 103.9 – Does the air conditioning make us sick? – Videos that have a significant impact for men with prostate cancer.
